Sirius Therapeutics
San Diego
About Sirius Therapeutics
Sirius Therapeutics develops RNA interference (RNAi) therapeutics, focusing on small interfering RNA (siRNA) molecules for treating cardiovascular diseases. The company’s pipeline includes SRSD107, targeting coagulation factor XI for thromboembolic disorders, and SRSD101, aimed at treating dyslipidemia. Sirius Therapeutics is also developing SRSD216 for hyperlipoproteinemia(a), a lipid disorder related to atherosclerotic cardiovascular disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $110.0M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2025)
- Website: siriusrna.com
- Phone: 858-358-0096
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/sirius-therapeutics-58893 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.